Trial Profile
A Pilot Study to Investigate the Potential of Buparid/PARI SINUS Versus Budes Nasal Spray to Avoid or Postpone Sinus Surgery in Adult Patients With Chronic Rhinosinusitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Budesonide (Primary) ; Budesonide (Primary)
- Indications Rhinosinusitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors PARI Pharma GmbH
- 14 Feb 2022 Status changed from active, no longer recruiting to completed.
- 24 Dec 2020 This trial has been completed in Germany as per European Clinical Trials Database record.
- 03 Apr 2018 Planned End Date changed from 1 May 2018 to 1 Jan 2019.